Related Experiment Video

Updated: Jun 4, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Directed therapy of subtypes of triple-negative breast cancer

Lisa A Carey1

  • 1University of North Carolina, Chapel Hill, North Carolina 27599-7305, USA. lisa_carey@med.unc.edu

The Oncologist
|February 1, 2011
PubMed

Insights

Triple-negative breast cancer (TNBC) has a poor prognosis, disproportionately causing deaths. New therapies targeting BRCA mutations and poly(ADP-ribose) polymerase inhibitors show promise for improving outcomes in TNBC patients.

Area of Science:

  • Oncology
  • Genetics

Background:

  • Breast cancer mortality has improved, primarily in estrogen receptor (ER)-positive and HER2-positive subtypes.
  • Triple-negative breast cancer (TNBC), lacking ER, progesterone receptor, and HER2, has a poorer prognosis and accounts for a disproportionate number of deaths.
  • The link between BRCA mutations and TNBC is under investigation.

Purpose of the Study:

  • To review the nature of triple-negative breast cancer.
  • To discuss current and emerging therapeutic strategies for TNBC.
  • To explore the role of BRCA mutations and novel drug classes in TNBC treatment.

Main Methods:

  • Review of recent studies on TNBC.
  • Analysis of therapeutic agents including chemotherapy, antiangiogenic agents, and poly(ADP-ribose) polymerase inhibitors.
  • Discussion of synthetic lethality in the context of BRCA-associated TNBC.

Main Results:

  • Chemotherapy is effective but research is ongoing for better targeted therapies.
  • Antiangiogenic agents like bevacizumab show efficacy across breast cancer subtypes.
  • Poly(ADP-ribose) polymerase inhibitors exploit synthetic lethality to target TNBC and BRCA-associated tumors.

Conclusions:

  • Targeted therapies are crucial for improving outcomes in triple-negative breast cancer.
  • Understanding the link between BRCA mutations and TNBC can lead to more effective treatment strategies.
  • Continued research into novel agents and treatment approaches is essential for advancing TNBC patient care.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.